Compare BridgeBio Pharma Inc (BBIO) vs Wheaton Precious Metals Corp (WPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Wheaton Precious Metals Corp — how do they compare? BridgeBio Pharma Inc trades at $84.12 (market cap $16.46B), while Wheaton Precious Metals Corp trades at $107.8 (market cap $48.84B). The key difference: Wheaton Precious Metals Corp is far larger — about 3× BridgeBio Pharma Inc's market cap, and Wheaton Precious Metals Corp pays a 0.72% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | WPM | |
|---|---|---|
Market Cap | $16.46B | $48.84B |
Sector | Health | Basic Materials |
52-Week High | $90.17 | $165.72 |
52-Week Low | $44.81 | $88.32 |
Enterprise Value | $18.02B | $46.68B |
Dividend Yield | — | 0.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
Wheaton Precious Metals (WPM) trades at $107.83, down 2.02% today, showing bearish technical signals with strong resistance at $108-$110. Fundamentally, the company demonstrates robust performance with Q1 2026 EPS beating expectations at $1.28 versus $1.24, continuing a trend of earnings surprises. Revenue grew to $2.31 billion in 2025 with impressive 65.55% net income margin, though valuation ratios remain elevated with P/E at 27.25.
The stock presents a compelling opportunity with 80% analyst buy ratings and $161.75 consensus price target, representing 50% upside potential. Key risks include precious metal price volatility and the bearish technical outlook. Record cash flow generation and strong production growth support the positive fundamental story despite near-term price pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Wheaton Precious Metals Corp
Wheaton Precious Metals Corp is a precious metal streaming company. The company has entered into over 20 long-term purchase agreements with 17 different mining companies, for the purchase of precious metals and cobalt. It has streaming agreements covering approximately 19 operating mines and 9 development stage projects. The company's projects include Vale's Salobo mine and silver streams on Glencore's Antamina mine and Goldcorp's Penasquito mine.
Read more on WPM →
